Logo Logo Logo Logo Logo
  • Home
  • Expertise
  • Consulting Services
  • Our Platforms
  • News
  • Careers
  • Contact
  • Home
  • Expertise
  • Consulting Services
  • Our Platforms
  • News
  • Careers
  • Contact
11 July, 2022 in News
China available as an optional add-on for Prismaccess
06 October, 2021 in News
Les nouvelles indications en oncologie peu accessibles au patient français
06 October, 2021 in News
New indications in oncology not easily accessible to French patients
19 March, 2021 in News
UK Cancer Drugs Fund to be expanded for non-cancer therapies
25 February, 2021 in News
Japan’s First Pricing Reform Since 2013, expected in April 2021
10 February, 2021 in News
Cost-effectiveness and budget impact to be included in new IPTs
20 January, 2021 in News
Innovative CAR-T cell therapy set to be reimbursed by NICE
14 January, 2021 in News
New routes to marketing approval in Great Britain
08 January, 2021 in News
Best wishes from Prioritis
12 February, 2020 in News
EMA after Brexit? Prioritis continues to monitor the changes
  • 1
  • 2
  • 3
  • 4
An IQVIA Business

logo
Contact us

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry dedicated to delivering actionable insights. Learn more at www.iqvia.com

Prioritis United Kingdom
United Kingdom
Prioritis Ltd
221 Pentonville Road King’s Cross
London N1 9JY – United Kingdom
tel. +44 7908 126 651
contact@prioritis.com
Prioritis France
France
Prioritis SAS
12 av Victor Hugo
75116 Paris
tel. +33 1 45 00 25 25 contact@prioritis.com